Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A dog model using an implanted system for protracted hepatic arterial chemotherapy.

I S Wollner, C A Knutsen, K A Ullrich

    The Journal of Surgical Research
    |November 1, 1986
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Design, synthesis and evaluation of diazadibenzocrown ethers as Pb(2+) extractants and carriers in plasticized cellulose triacetate membranes.

    Talanta·2008
    Same author

    Absorption, tissue distribution, metabolism and elimination of taurine given orally to rats.

    Amino acids·2007
    Same author

    CAM providers' messages to conventional medicine: a qualitative study.

    American journal of medical quality : the official journal of the American College of Medical Quality·2002
    Same author

    Introduction of Dr. William C. Wood.

    Annals of surgical oncology·2001
    Same author

    The future for staging of primary tumors.

    Annals of surgical oncology·2001
    Same author

    Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.

    International journal of radiation oncology, biology, physics·2001

    Researchers developed a new way to test cancer drugs by implanting a specialized pump in dogs to deliver medication directly to the liver. This method allows for long-term study of drug safety and effectiveness in a way that mimics human treatment. The approach is safe for the animals and provides a reliable platform for future cancer therapy development.

    Area of Science:

    • Veterinary medicine and hepatic arterial chemotherapy research
    • Oncology and pharmacology within translational medicine

    Background:

    No prior work had resolved how to consistently deliver long-term regional cancer treatments in large animal models. Current methods often struggle with maintaining stable drug concentrations within the liver over extended periods. This uncertainty drove the need for a reliable, implantable system that mimics clinical human scenarios. Prior research has shown that regional delivery can improve drug efficacy while minimizing systemic side effects. However, existing models frequently lacked the longevity required for comprehensive pharmacokinetic assessments. This gap motivated the development of a surgical technique using large dogs to bridge the translational divide. Investigators required a platform that allowed for repeated, controlled administration of chemotherapeutic agents. Establishing such a model provides a necessary foundation for evaluating new cytotoxic therapies before human clinical trials.

    Purpose Of The Study:

    The aim of this work was to establish a canine model for conducting hepatic arterial chemotherapy studies using an implantable infusion system. Researchers sought to create a platform that allows for protracted drug delivery directly to the liver. This initiative addresses the need for reliable preclinical testing of chemotherapeutic agents in a large animal model. The team intended to mimic the delivery methods currently used in human clinical settings. By developing this technique, they aimed to facilitate comprehensive pharmacokinetic and toxicologic evaluations. The motivation stemmed from the requirement to examine new treatment modalities in a controlled, long-term environment. Investigators focused on ensuring that the surgical implantation did not compromise the health or behavior of the subjects. Ultimately, the study provides a means to refine cytotoxic therapies directed at the tumor vascular bed.

    Keywords:
    canine modelpharmacokineticstoxicologyliver cancer therapypreclinical research

    Frequently Asked Questions

    The researchers propose that the system achieves near-complete perfusion, exceeding 90% of the liver volume. This was confirmed through hepatic arterial perfusion scintigraphy using technetium 99m macroaggregated albumin as a tracer.

    The team utilizes an implantable infusion pump to deliver medication. This device allows for the sustained, protracted administration of chemotherapeutic agents directly into the hepatic artery, mimicking clinical human delivery systems.

    The authors state that precise catheter placement is necessary to ensure proper drug distribution. This technical requirement prevents perfusion failures and ensures that the therapeutic agent reaches the target vascular bed effectively.

    The researchers use pre- and post-operative serum glutamic-pyruvic transaminase and alkaline phosphatase levels to monitor liver health. These biochemical markers provide data on potential acute organ damage following the surgical implantation procedure.

    Related Experiment Videos

    Main Methods:

    The review approach involved developing a surgical technique to place an infusion device within large canine subjects. Investigators performed catheterization of the hepatic artery to facilitate localized drug delivery. The team utilized hepatic arterial perfusion scintigraphy to verify the distribution of the therapeutic agents. They employed technetium 99m macroaggregated albumin to visualize the extent of liver coverage. Clinical staff monitored the animals for changes in mobility or behavioral patterns throughout the study duration. Researchers analyzed serum glutamic-pyruvic transaminase and alkaline phosphatase levels to evaluate potential organ toxicity. The study design incorporated a range of 52 to 239 days for monitoring individual subjects. Scientists also assessed the physicochemical properties of the loaded solutions to ensure compatibility with the pump mechanism.

    Main Results:

    Key findings from the literature indicate that the model achieves greater than 90% perfusion of the liver. The system demonstrated reliability over a total of 1353 days of cumulative use. Individual subjects maintained the device for a mean duration of 104 days. Data showed no evidence of acute liver damage following the surgical implantation procedure. Post-operative biochemical markers remained stable compared to pre-operative baseline values. The implanted hardware did not interfere with the natural mobility or behavior of the canine subjects. Success depended on the precise placement of the catheter within the arterial system. The researchers observed that the physicochemical characteristics of the infused solutions influenced the overall performance of the model.

    Conclusions:

    The authors propose that this canine model offers a robust platform for evaluating regional cancer therapies. Synthesis and implications suggest that the system supports long-term pharmacokinetic and toxicologic investigations. Researchers believe the device successfully mimics the delivery methods utilized in human clinical practice. The team indicates that careful surgical catheter positioning remains a primary factor for achieving high perfusion rates. Evidence shows that the implanted pump does not negatively impact the general health or mobility of the subjects. The study implies that this approach facilitates the development of more potent treatments directed at tumor vascular beds. Findings suggest that the model is suitable for testing both novel and established chemotherapeutic compounds. The authors conclude that this technique provides a valuable tool for advancing preclinical oncology research.

    The study reports a mean duration of 104 days for the system, with a total usage period reaching 1353 days across 13 subjects. This measurement demonstrates the long-term reliability of the implanted hardware.

    The authors claim that this model enables the design of more potent cytotoxic therapies. By allowing for comprehensive preclinical testing, the system helps refine treatment modalities before they are applied to human patients.